CAS: 7314-85-4; 2-Bromoadamantane

相似化合物

768-90-1 707-34-6 7314-86-5

上下游产品

CAS号935-56-8 1-氯代金刚烷 | CAS号866942-25-8 2-adamantyl 2-(... | CAS号31616-68-9 2-adamantyl met... | CAS号25139-43-9 2-adamantyl 4-m... | CAS号700-57-2 2-金刚烷醇 | CAS号281-23-2 金刚烷 | CAS号1643-19-2 四丁基溴化铵 | CAS号937-14-4 间氯过氧苯甲酸 | CAS号105419-86-1 2-金刚烷-2-基-2-丙醇 | CAS号21517-94-2 ac1l3htk | CAS号19066-24-1 2-苯基金刚烷 | CAS号89755-12-4 Stannane, triph... | CAS号1064-10-4 六苯基二锡 | CAS号281-23-2 金刚烷 | CAS号700-56-1 2-甲基金刚烷 | CAS号29844-85-7 tricyclo[4.3.1.... | CAS号19066-23-0 Adamantylmethylether

2-金刚烷醇置于吡啶,1-丁基-3-甲基咪唑溴盐体系中,化学反应 24.0H,反应生成 2-溴代金刚烷
参考文献:可回收离子液体 [bmim][x] 磺酸酯亲核取代反应的简便绿色方案
标题:可回收离子液体 [bmim][x] 磺酸酯亲核取代反应的简便绿色方案
摘要:离子液体 [bmim][x] (X = Cl,Br,I,Oac,Scn) 是用于伯醇和仲醇衍生的磺酸酯亲核取代反应的高效试剂.离子液体的抗衡阴离子 (X-) [bmim][x] 有效地替代了磺酸盐,以优异的产率提供了相应的取代产物,如烷基卤化物,乙酸盐和硫氰化物.新开发的协议对环境非常有吸引力,因为在大多数情况下,反应使用化学计量的离子液体作为唯一试剂,不需要额外的溶剂,任何其他活化试剂,非常规设备或特殊预防措施.此外,这些离子液体可以很容易地回收利用而不会损失反应性,从而使整个过程"更环保".
DOI:10.1055/s-0032-1317473

专利信息

专利号:WO-2025132776-A1
优先权日:2023-12-20
标题 :Use of iron-based compounds for the synthesis of borated compounds, and corresponding methods
发明人：HANNEDOUCHE JÉRÔME; BEZZENINE SOPHIE; GIL RICHARD; CHEN DONGHUANG; WOWK VINCENT
权利人:UNIV PARIS SACLAY; CENTRE NAT RECH SCIENT
摘要:The present invention relates to the use of iron-based compounds for the synthesis of borated compounds, and the corresponding methods.

专利号:US-6524551-B2
优先权日:2001-01-26
标 题:Synthesis of MCM-58
发明人：DHINGRA SANDEEP S
权利人:EXXONMOBIL OIL CORP
摘要:This invention provides a process for the synthesis of MCM-58 using 1-(1-adamantyl)pyridinium cations as a directing agent. The resultant MCM-58 is useful in a variety of hydrocarbon conversion reactions including toluene disproportionation, transalkylation of aromatics, reaction of paraffins with aromatics, paraffin isomerization and alkylation of aromatics with olefins.

专利号:US-2003203915-A1
优先权日:2002-04-05
标题 :Nitric oxide donors, compositions and methods of use related applications
发明人：FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; LIN CHIA-EN; RANATUNGA RAMANI R; RICHARDSON STEWART K; WANG TIANSHENG; WANG WEIHENG; WEY SHIOW-JYI
权利人:FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; LIN CHIA-EN; RANATUNGA RAMANI R; RICHARDSON STEWART K; WANG TIANSHENG; WANG WEIHENG; WEY SHIOW-JYI
摘要:The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

专利号:US-2008125354-A1
优先权日:2005-11-21
标题 :Selective inhibition of matrix metalloproteinases
发明人：FIELDS GREGG B; HAMMER ROBERT
权利人:UNIV FLORIDA ATLANTIC; UNIV LOUISIANA STATE
摘要:Synthetic triple-helical peptides (THPs) are used for the design and synthesis of triple-helical transition state analog inhibitors. These inhibitors feature a phosphonate ester or phosphinic moiety in place of the scissle bond. These groups inhibit MMPs, and methods been developed for their convenient incorporation within a peptide sequence by solid-phase methods.

专利号:US-5599998-A
优先权日:1994-10-24
标 题:Method for the synthesis of adamantane amines
发明人：KRAUS GEORGE A
权利人:UNIV IOWA STATE RES FOUND INC
摘要:The present invention provides a method to prepare aminated bridgehead polycyclic hydrocarbons by reacting bridgehead halo polycyclic hydrocarbons with lithium metal under conditions of sonication and aminating the resultant lithio compounds.

专利号:US-2005085555-A1
优先权日:1997-08-21
标 题:Composition, synthesis and therapeutic applications of polyamines
发明人：MURPHY MICHAEL A; MALACHOWSKI MITCHELL R
摘要:This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.